{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:33:29Z","timestamp":1790706809810,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007680","name":"Universidad P\u00fablica de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007680","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Endometrial or uterine\u00a0cancers predominantly occur in postmenopausal women, thereby establishing a strong correlation with advanced age. The chemotherapeutic agents ifosfamide and 5-fluorouracil have demonstrated notable efficacy against endometrial cancer by inhibiting cell division and proliferation. Nevertheless, current pharmacological treatments encounter challenges related to drug resistance and adverse effects. To assess the potential of drug modifications, in silico methodologies were employed to alter the molecular structures of ifosfamide and 5-fluorouracil with the aim of enhancing their efficacy and binding affinity to type 1 endometrial cancer. The three-dimensional configurations of mutated KRAS proteins were sourced from the Protein Data Bank. The molecular structures of ifosfamide and 5-fluorouracil were obtained from PubChem and EMBL-EBI, and subsequently modified using Chemsketch. The modifications included the addition of a methyl group, benzene ring, nitrogen atom, cyclopentane ring, and fluorine atoms to the drugs. The binding affinities of these modified drugs to the proteins were visualized using AutoDock Vina. The modified drugs exhibited improved binding affinities of \u22127.4 and \u22127.5 kcal\/mol with both mutated target proteins. SwissADME analysis and Molinspiration\u2019s evaluation of Lipinski\u2019s rule parameters suggested that these modified drugs hold promise for the treatment of type 1 endometrial cancer, pending preclinical and clinical trials. This study represents a significant advancement in drug modification as a potential chemotherapeutic strategy for endometrial cancer. Among the two modified drugs, altered 5-fluorouracil demonstrated superior binding affinity and pharmacokinetic properties, rendering it a promising candidate.<\/jats:p>","DOI":"10.1007\/s12032-025-02821-2","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T01:27:44Z","timestamp":1750814864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Enhancing the therapeutic potential of FDA-approved ifosfamide and 5-fluorouracil through rational chemical modifications for endometrial cancer treatment"],"prefix":"10.1007","volume":"42","author":[{"given":"Laiba","family":"Tanveer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Batool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mubeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izzah","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"2","key":"2821_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ygyno.2014.05.018","volume":"134","author":"WM Burke","year":"2014","unstructured":"Burke WM, Fu J, Poliak A, Smith MT. Endometrial cancer: A review and current management strategies: Part I. Gynecol Oncol. 2014;134(2):385\u201392. https:\/\/doi.org\/10.1016\/j.ygyno.2014.05.018.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2821_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/1055-9965.EPI-16-0858","volume":"26","author":"LA Torre","year":"2017","unstructured":"Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444\u201357. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-0858.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2821_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"2821_CR4","doi-asserted-by":"publisher","first-page":"9059","DOI":"10.3390\/ijerph19159059","volume":"19","author":"A Abdol Manap","year":"2022","unstructured":"Abdol Manap A, Wahab NA, Abdullah NA, Ibrahim H, Mohd Nor N, Wan Ibrahim WZ. Endometrial cancer in pre-menopausal women and younger: Risk factors and outcome. Int J Environ Res Public Health. 2022;19(15):9059. https:\/\/doi.org\/10.3390\/ijerph19159059.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2821_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40644-018-0180-6","volume":"18","author":"S Rizzo","year":"2018","unstructured":"Rizzo S, Perra L, Salvatore V, et al. Endometrial cancer: An overview of novelties in treatment and related imaging keypoints for local staging. Cancer Imaging. 2018;18(1):45. https:\/\/doi.org\/10.1186\/s40644-018-0180-6.","journal-title":"Cancer Imaging"},{"issue":"9","key":"2821_CR6","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/bjc.2011.68","volume":"104","author":"H Evans","year":"2011","unstructured":"Evans H, Loughrey M, Luesley D, et al. Differential trends in the rising incidence of endometrial cancer by type: Data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011;104(9):1505\u201310. https:\/\/doi.org\/10.1038\/bjc.2011.68.","journal-title":"Br J Cancer"},{"issue":"4","key":"2821_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/AOG.0000000000004711","volume":"139","author":"D Chelmow","year":"2022","unstructured":"Chelmow D, Powell M, Montoya G, et al. Executive summary of the uterine cancer evidence review conference. Obstet Gynecol. 2022;139(4):626\u201343. https:\/\/doi.org\/10.1097\/AOG.0000000000004711.","journal-title":"Obstet Gynecol"},{"key":"2821_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/B978-0-12-803741-6.00011-2","volume-title":"Translational advances in gynecologic cancers","author":"ME Urick","year":"2017","unstructured":"Urick ME, Bell DW. Endometrial cancer genomics. In: Vassilakos TP, editor. Translational advances in gynecologic cancers. Amsterdam: Elsevier; 2017. p. 199\u2013227."},{"issue":"20","key":"2821_CR9","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","volume":"31","author":"VW Setiawan","year":"2013","unstructured":"Setiawan VW, Pike MC, Yang HP, et al. Type I and II endometrial cancers: Have they different risk factors? J Clin Oncol. 2013;31(20):2607\u201318. https:\/\/doi.org\/10.1200\/JCO.2012.48.2596.","journal-title":"J Clin Oncol"},{"key":"2821_CR10","first-page":"405","volume-title":"Treatment of cancer","author":"C Fotopoulou","year":"2014","unstructured":"Fotopoulou C, Gabra H. Endometrial cancer. In: Enochson J, editor. Treatment of cancer. 6th ed. Boca Raton: CRC Press; 2014. p. 405\u201316.","edition":"6"},{"issue":"2","key":"2821_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/0976-7800.185335","volume":"7","author":"FD Lobo","year":"2016","unstructured":"Lobo FD, Thomas E. Type II endometrial cancers: A case series. J Mid-Life Health. 2016;7(2):69\u201372. https:\/\/doi.org\/10.4103\/0976-7800.185335.","journal-title":"J Mid-Life Health"},{"issue":"1","key":"2821_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/whe.13.72","volume":"10","author":"J Black","year":"2014","unstructured":"Black J, Bell D, Katz R, et al. Targeted therapy in uterine serous carcinoma: An aggressive variant of endometrial cancer. Womens Health (Lond). 2014;10(1):45\u201357. https:\/\/doi.org\/10.2217\/whe.13.72.","journal-title":"Womens Health (Lond)"},{"key":"2821_CR13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1201\/b19647-107","volume-title":"Obstetrics and gynaecology: An evidence-based text for MRCOG","author":"M Gurumurthy","year":"2016","unstructured":"Gurumurthy M, Cruickshank M. Endometrial cancer. In: Obstetrics and gynaecology: An evidence-based text for MRCOG. 3rd ed. Boca Raton: CRC Press; 2016. p. 873\u201382.","edition":"3"},{"issue":"5","key":"2821_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/PAS.0b013e318247b7bb","volume":"36","author":"R Alvarez","year":"2012","unstructured":"Alvarez R, Zhang M, Hsu L, et al. Molecular profile of grade 3 endometrioid endometrial carcinoma. Am J Surg Pathol. 2012;36(5):753\u201361. https:\/\/doi.org\/10.1097\/PAS.0b013e318247b7bb.","journal-title":"Am J Surg Pathol"},{"key":"2821_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2023.09.009","volume":"178","author":"K Whelan","year":"2023","unstructured":"Whelan K, Dillon M, Strickland KC, Pothuri B, Bae-Jump V, Borden LE, Thaker PH, Haight P, Arend RC, Ko E, Jackson AL. TP53 mutation and abnormal p53 expression in endometrial cancer: associations with race and outcomes. Gynecol Oncol. 2023;178:44\u201353. https:\/\/doi.org\/10.1016\/j.ygyno.2023.09.009.","journal-title":"Gynecol Oncol"},{"issue":"14","key":"2821_CR16","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/hmg\/ddx106","volume":"26","author":"Y Zerdoumi","year":"2017","unstructured":"Zerdoumi Y, Lanos R, Raad S, Flaman JM, Bougeard G, Frebourg T, Tournier I. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Hum Mol Genet. 2017;26(14):2591\u2013602. https:\/\/doi.org\/10.1093\/hmg\/ddx106.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2821_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41467-023-44239-2","volume":"15","author":"M Zhao","year":"2024","unstructured":"Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun. 2024;15(1):180. https:\/\/doi.org\/10.1038\/s41467-023-44239-2.","journal-title":"Nat Commun"},{"key":"2821_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100593","volume":"33","author":"A Laibangyang","year":"2020","unstructured":"Laibangyang A, Alter R, Hasan Y, Yamada SD. Superior vena cava syndrome associated with uterine serous carcinoma. Gynecol Oncol Rep. 2020;33: 100593. https:\/\/doi.org\/10.1016\/j.gore.2020.100593.","journal-title":"Gynecol Oncol Rep"},{"issue":"10","key":"2821_CR19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2174\/1566524013666131111125515","volume":"13","author":"H Chen","year":"2013","unstructured":"Chen H, Yu Y, Wang Z, et al. Platinum-based agents for individualized cancer treatment. Curr Mol Med. 2013;13(10):1603\u201312. https:\/\/doi.org\/10.2174\/1566524013666131111125515.","journal-title":"Curr Mol Med"},{"issue":"33","key":"2821_CR20","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1200\/JCO.20.01076","volume":"38","author":"DS Miller","year":"2020","unstructured":"Miller DS, Dizon DS, Fowler JM, et al. Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209). J Clin Oncol. 2020;38(33):3841\u201350. https:\/\/doi.org\/10.1200\/JCO.20.01076.","journal-title":"J Clin Oncol"},{"key":"2821_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/B978-0-12-824299-5.00013-7","volume-title":"Overcoming drug resistance in gynecologic cancers","author":"MI Arain","year":"2021","unstructured":"Arain MI, Khan R, Khalid F, et al. Chemoresistance in uterine cancer: Mechanisms of resistance and current therapies. In: Overcoming drug resistance in gynecologic cancers. Amsterdam: Elsevier; 2021. p. 267\u201381."},{"issue":"5","key":"2821_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1272\/jnms.JNMS.2020_87-508","volume":"87","author":"T Asano","year":"2020","unstructured":"Asano T. Drug resistance in cancer therapy and the role of epigenetics. J Nippon Med Sch. 2020;87(5):244\u201351. https:\/\/doi.org\/10.1272\/jnms.JNMS.2020_87-508.","journal-title":"J Nippon Med Sch"},{"key":"2821_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/282570","volume":"2012","author":"K Sak","year":"2012","unstructured":"Sak K. Chemotherapy and dietary phytochemical agents. Chemother Res Pract. 2012;2012:1\u201311. https:\/\/doi.org\/10.1155\/2012\/282570.","journal-title":"Chemother Res Pract"},{"key":"2821_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.53388\/MDM202508008","volume":"8","author":"S Ahmad","year":"2025","unstructured":"Ahmad S, Bano N, Raza K. RCSB Protein Data Bank: revolutionising drug discovery and design for over five decades. Med Data Mining. 2025;8:7\u201311. https:\/\/doi.org\/10.53388\/MDM202508008.","journal-title":"Med Data Mining"},{"issue":"5","key":"2821_CR25","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1080\/07391102.2023.2209673","volume":"42","author":"S Ahmad","year":"2024","unstructured":"Ahmad S, Singh V, Gautam HK, Raza K. Multisampling-based docking reveals Imidazolidinyl urea as a multitargeted inhibitor for lung cancer: An optimisation followed multi-simulation and in-vitro study. J Biomol Struct Dyn. 2024;42(5):2494\u2013511. https:\/\/doi.org\/10.1080\/07391102.2023.2209673.","journal-title":"J Biomol Struct Dyn"},{"issue":"3","key":"2821_CR26","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s11030-023-10648-0","volume":"28","author":"S Ahmad","year":"2024","unstructured":"Ahmad S, Raza K. Identification of 5-nitroindazole as a multitargeted inhibitor for CDK and transferase kinase in lung cancer: A multisampling algorithm-based structural study. Mol Divers. 2024;28(3):1189\u2013202. https:\/\/doi.org\/10.1007\/s11030-023-10648-0.","journal-title":"Mol Divers"},{"issue":"7","key":"2821_CR27","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3109\/03639045.2013.789908","volume":"40","author":"MW Harrold","year":"2014","unstructured":"Harrold MW, Zavod RM. Basic concepts in medicinal chemistry. Drug Dev Ind Pharm. 2014;40(7):988. https:\/\/doi.org\/10.3109\/03639045.2013.789908.","journal-title":"Drug Dev Ind Pharm"},{"issue":"7","key":"2821_CR28","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1021\/acsomega.1c06394","volume":"7","author":"M Kurasaka","year":"2022","unstructured":"Kurasaka M, Kawakami Y, Abe T, et al. Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil. ACS Omega. 2022;7(7):6046\u201352. https:\/\/doi.org\/10.1021\/acsomega.1c06394.","journal-title":"ACS Omega"},{"key":"2821_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/978-3-642-16483-5_182","volume-title":"Encyclopedia of cancer","author":"L Sreerama","year":"2011","unstructured":"Sreerama L. Alkylating agents. In: Encyclopedia of cancer. Berlin: Springer; 2011. p. 132\u20136."},{"issue":"1","key":"2821_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-022-00795-0","volume":"16","author":"M Fekadu","year":"2022","unstructured":"Fekadu M, Abate D, Zewdie B, et al. Synthesis, in silico molecular docking analysis, pharmacokinetic properties and evaluation of antibacterial and antioxidant activities of fluoroquinolines. BMC Chem. 2022;16(1):1. https:\/\/doi.org\/10.1186\/s13065-022-00795-0.","journal-title":"BMC Chem"},{"issue":"1","key":"2821_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1021\/acsomega.0c05353","volume":"6","author":"O Olademehin","year":"2021","unstructured":"Olademehin O, Shittu T, Ogunyemi S, et al. Molecular dynamics simulation of atomic interactions in the vancomycin binding site. ACS Omega. 2021;6(1):775\u201385. https:\/\/doi.org\/10.1021\/acsomega.0c05353.","journal-title":"ACS Omega"},{"key":"2821_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.141703","volume":"306","author":"S Ahmad","year":"2025","unstructured":"Ahmad S, Bano N, Raza K. Evaluating the polypharmacological potency of FEDPN from ChEMBL BioAssays against lung cancer EGFR, ALK, TrkA and KRAS proteins. Int J Biol Macromol. 2025;306: 141703. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.141703.","journal-title":"Int J Biol Macromol"},{"issue":"24","key":"2821_CR33","doi-asserted-by":"publisher","first-page":"8895","DOI":"10.1073\/pnas.1404639111","volume":"111","author":"JC Hunter","year":"2014","unstructured":"Hunter JC, Carrasco MA, Lito P, et al. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A. 2014;111(24):8895\u2013900. https:\/\/doi.org\/10.1073\/pnas.1404639111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2821_CR34","first-page":"1","volume":"8","author":"WS Alnweny","year":"2024","unstructured":"Alnweny WS, Almayali MQ, Dakhil MA, et al. A study of biochemical markers in uterine cancer diagnosis with radiotherapy treatment in Iraq. J Angiother. 2024;8(3):1\u20138.","journal-title":"J Angiother"},{"issue":"27","key":"2821_CR35","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.2174\/0929867328666210211164314","volume":"28","author":"W Cardona-G","year":"2021","unstructured":"Cardona-G W, Herrera-R A, Castrill\u00f3n-L W, Ram\u00edrez-Malule H. Chemistry and anticancer activity of hybrid molecules and derivatives based on 5-fluorouracil. Curr Med Chem. 2021;28(27):5551\u2013601. https:\/\/doi.org\/10.2174\/0929867328666210211164314.","journal-title":"Curr Med Chem"},{"issue":"1","key":"2821_CR36","first-page":"22","volume":"1","author":"MA Al-Musali","year":"2017","unstructured":"Al-Musali MA. Role of angiogenesis on uterine fibroids therapy: Review. Integr Biomed Res. 2017;1(1):22\u20136.","journal-title":"Integr Biomed Res"},{"issue":"12","key":"2821_CR37","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1080\/09553002.2019.1524945","volume":"94","author":"MA Motaleb","year":"2018","unstructured":"Motaleb MA, El-Safoury DM, Abd-Alla WH, Awad GA, Sakr TM. Radiosynthesis, molecular modeling studies and biological evaluation of 99mTc-Ifosfamide complex as a novel probe for solid tumor imaging. Int J Radiation Biol. 2018;94(12):1134\u201341. https:\/\/doi.org\/10.1080\/09553002.2019.1524945.","journal-title":"Int J Radiation Biol"},{"issue":"5","key":"2821_CR38","first-page":"1","volume":"8","author":"T Al Hair","year":"2024","unstructured":"Al Hair T, Hadisaputra W, et al. Apoptotic pathways and anti-M\u00fcllerian hormone affects the ovarian tissue damage during endometrioma cystectomy. J Angiother. 2024;8(5):1\u201318.","journal-title":"J Angiother"},{"issue":"3","key":"2821_CR39","first-page":"1","volume":"8","author":"AV Poznyak","year":"2024","unstructured":"Poznyak AV, Sukhorukov VN, Sobenin IA, et al. Exploring the link between chronic inflammation and atherosclerosis-endometriosis association. J Angiother. 2024;8(3):1\u20138.","journal-title":"J Angiother"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02821-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02821-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02821-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:41:01Z","timestamp":1757198461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02821-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2821"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02821-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"281"}}